BACKGROUND: This study examined drug interactions between buprenorphine, a partial opioid agonist used for opioid dependence treatment and pain management, and the protease inhibitors (PIs) darunavir-ritonavir and fosamprenavir-ritonavir. METHODS: The pharmacokinetics of buprenorphine and its metabolites and symptoms of opioid withdrawal or excess were compared in opioid-dependent, buprenorphine-naloxone-maintained, human immunodeficiency virus (HIV)-negative volunteers (11 for darunavir-ritonavir and 10 for fosamprenavir-ritonavir) before and after 15 days of PI administration. PI pharmacokinetics and adverse effects were compared between the buprenorphine-maintained participants and an equal number of sex-, age-, race-, and weight-matched, healthy, non-opioid-dependent volunteers who received darunavir-ritonavir or fosamprenavir-ritonavir but not buprenorphine. RESULTS: There were no significant changes in buprenorphine or PI plasma levels and no significant changes in medication adverse effects or opioid withdrawal. Increased concentrations of the inactive metabolite buprenorphine-3-glucuronide suggested that darunavir-ritonavir and fosamprenavir-ritonavir induced glucuronidation of buprenorphine. CONCLUSIONS: Dose adjustments are not likely to be necessary when buprenorphine and darunavir-ritonavir or fosamprenavir-ritonavir are coadministered for the treatment of opioid dependence and HIV disease.
BACKGROUND: This study examined drug interactions between buprenorphine, a partial opioid agonist used for opioid dependence treatment and pain management, and the protease inhibitors (PIs) darunavir-ritonavir and fosamprenavir-ritonavir. METHODS: The pharmacokinetics of buprenorphine and its metabolites and symptoms of opioid withdrawal or excess were compared in opioid-dependent, buprenorphine-naloxone-maintained, human immunodeficiency virus (HIV)-negative volunteers (11 for darunavir-ritonavir and 10 for fosamprenavir-ritonavir) before and after 15 days of PI administration. PI pharmacokinetics and adverse effects were compared between the buprenorphine-maintained participants and an equal number of sex-, age-, race-, and weight-matched, healthy, non-opioid-dependent volunteers who received darunavir-ritonavir or fosamprenavir-ritonavir but not buprenorphine. RESULTS: There were no significant changes in buprenorphine or PI plasma levels and no significant changes in medication adverse effects or opioid withdrawal. Increased concentrations of the inactive metabolite buprenorphine-3-glucuronide suggested that darunavir-ritonavir and fosamprenavir-ritonavir induced glucuronidation of buprenorphine. CONCLUSIONS: Dose adjustments are not likely to be necessary when buprenorphine and darunavir-ritonavir or fosamprenavir-ritonavir are coadministered for the treatment of opioid dependence and HIV disease.
Authors: Vanitha Sekar; Frank Tomaka; Eric Lefebvre; Martine De Pauw; Tony Vangeneugden; Wim van den Brink; Richard Hoetelmans Journal: J Clin Pharmacol Date: 2010-04-26 Impact factor: 3.126
Authors: J Andrew Williams; Ruth Hyland; Barry C Jones; Dennis A Smith; Susan Hurst; Theunis C Goosen; Vincent Peterkin; Jeffrey R Koup; Simon E Ball Journal: Drug Metab Dispos Date: 2004-08-10 Impact factor: 3.922
Authors: David E Moody; Matthew H Slawson; Eric C Strain; John D Laycock; Alan C Spanbauer; Rodger L Foltz Journal: Anal Biochem Date: 2002-07-01 Impact factor: 3.365
Authors: R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland Journal: Expert Rev Clin Pharmacol Date: 2013-05 Impact factor: 5.045
Authors: Lynn E Taylor; Michaela A Maynard; Peter D Friedmann; Cynthia J Macleod; Josiah D Rich; Timothy P Flanigan; Diana L Sylvestre Journal: J Addict Med Date: 2012-09 Impact factor: 3.702
Authors: Lori A Gordon; Christine Y Malati; Colleen Hadigan; Mary McLaughlin; Raul M Alfaro; Mónica M Calderón; Joseph A Kovacs; Scott R Penzak Journal: Pharmacotherapy Date: 2016-01 Impact factor: 4.705
Authors: Mari Fihlman; Tuija Hemmilä; Nora M Hagelberg; Janne T Backman; Jouko Laitila; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari Journal: Eur J Clin Pharmacol Date: 2018-08-30 Impact factor: 2.953
Authors: Stephen S Dominy; Joseph N Brown; Mark I Ryder; Marina Gritsenko; Jon M Jacobs; Richard D Smith Journal: PLoS One Date: 2014-04-09 Impact factor: 3.240